Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
40S ribosomal protein S9 (RPS9)
- Target
- RPS9
- Molecular classification
- Other (Structural constituent of ribosome), Ribosomal protein, S4P family of ribosomal proteins
01
Overview
40S ribosomal protein S9 (RPS9) is a component of the small (40S) subunit of the eukaryotic ribosome. It plays a crucial role in ribosome biogenesis, directly binds ribosomal RNA during early ribosome assembly, and is essential for the translation of mRNA into proteins within the cytoplasm. RPS9 is part of the S4P family of ribosomal proteins and is highly conserved across eukaryotes, prokaryotes (as RPS4), and archaea. In human cells, RPS9 is detected in both the nucleolus (site of ribosome assembly) and the cytoplasm (site of active translation). Mutations or depletion of RPS9 disrupt ribosome production, impair cell proliferation, and can induce cell cycle arrest or apoptosis. Variable expression has been observed in certain cancers, such as colorectal cancer, and it has mechanistic roles in diseases like Diamond-Blackfan anemia and Takayasu arteritis
- Other names
- Small ribosomal subunit protein uS4uS4S9Ribosomal protein S940S ribosomal protein S9
02
Mechanism of action
Not applicable; no drugs are known to selectively target or modulate RPS9 specifically
03
Biological functions
Ribosome biogenesisProtein synthesis (translation)Positive regulation of cell proliferationRNA binding
04
Disease associations
Cancer (variable expression reported in colorectal cancer)Diamond-Blackfan anemiaTakayasu arteritisOther (its dysregulation is associated more broadly with ribosomopathies and cellular stress responses)
05
Safety considerations
Targeting ribosomal proteins like RPS9 may disrupt global protein synthesis, leading to cellular toxicity, impaired proliferation, and apoptosis. This reflects a general challenge for "housekeeping" or essential proteins rather than specific safety signals for RPS9
06
Interacting drugs
None known directly targeting RPS9
07
Biomarkers
Changes in RPS9 expression have been noted in some cancers, e.g., colorectal cancer, but it is not established as a diagnostic or predictive biomarker
Beyond the preview
Go deeper on 40S ribosomal protein S9 (RPS9).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 40S ribosomal protein S9 (RPS9).